Diabetic Neuropathy Market to Rise at 8.9% till 2026; Increasing Number of Regulatory Approvals Will Aid Growth, says Fortune Business Insights™

Key Companies Covered in the Diabetic Neuropathy Market Research Report are Abbott, Eli Lilly and Company, Pfizer.Inc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Astellas Pharma US, Inc. and other key market players.


Pune, May 05, 2020 (GLOBE NEWSWIRE) -- The global diabetic neuropathy market size is projected to reach USD 7.12 billion by the end of 2026. The highest prevalence of diabetes will bode well for the market in the coming years. According to a report published by Fortune Business Insights, titled “Diabetic Neuropathy Market Size, Share & Industry Analysis, By Disease Type (Peripheral, Autonomic, Proximal, and Focal), By Drug Class (Anti-Depressants, Anti-Seizures, Opioid, Non-Steroidal Anti-Inflammatory, and others), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Online Pharmacies), and Regional Forecast, 2019-2026,” the market was worth USD 3.61 billion and will exhibit a CAGR of 8.9% during the forecast period, 2019-2026.

Request a Sample Copy of the Research Report:

Diabetic neuropathy is a severe disorder that mostly occurs in diabetic patients. It leads to nerve damage in legs and feet of the human body. As feet and legs are sensitive parts of the body, there is a huge focus on early detection and precaution of the disease. Besides nerve damages, the disorder has the potential to affect the digestive system and also have adverse effects on the urinary tract and heart. Accounting to the severity of the disease, regulatory authorities are compelled to approve more products and therapeutic procedures associated with the disease.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

To get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/diabetic-neuropathy-market-100598

The high prevalence of diabetic neuropathy, mostly in diabetic patients, will create several growth opportunities for the companies operating in this market. According to the World Health Organization, the total number of diabetic patients is likely to research an estimated 430 million by the end of 2030. Additionally, the effect of diabetic neuropathy on sensitive parts of the human body will attract more companies as well as researchers.

Increasing Number of Regulatory Approvals Will Aid Growth

The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the increasing number of product approvals by regulatory authorities across the world has made the highest impact. In July 2019, Averitas Pharma announced that it received approval from the US Food and Drug Administration for a new product associated with the treatment of neuropathic pain associated with therapeutic procedures. The company received approval for ‘Quentaza’, a drug used to minimize pain in peripheral diabetic neuropathy. Averitas’ latest product will bode well for the market in the foreseeable future.

Quick Buy -  Diabetic Neuropathy Market Research Report:

North America to Emerge Dominant; Increasing Number of Diabetic Patients Will Provide Impetus to Market Growth

The report analyzes the ongoing diabetic neuropathy market trends across North America, Latin America, Asia Pacific, the Middle East and Africa, and Europe. Among these regions, the market in North America is likely to emerge dominant in the coming years. The high prevalence of diabetic in several countries across this region will aid the growth of the market. As of 2018, the market in North America was worth USD 2.19 billion and this value is likely to increase further in the coming years. The market in Asia Pacific will exhibit the highest CAGR in the coming years, driven by the increasing R&D activities in several countries across this region.

List of Key Companies Operating in the Diabetic Neuropathy Market are:

  • Abbott
  • Eli Lilly and Company
  • Pfizer.Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Astellas Pharma US, Inc.
  • Others

Industry Developments:

July 2019: Laurus Labs Limited announced that it has launched newer version of its pain management capsules for patients suffering from diabetic neuropathy.

Have Any Query? Ask Our Experts:

Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
    • New Product Launches
    • Prevalence of Diabetic Neuropathy
    • Pipeline Analysis
  • Global Diabetic Neuropathy Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Disease Type
      • Peripheral
      • Autonomic
      • Proximal
      • Focal
    • Market Analysis, Insights and Forecast – By Drug Class
      • Non-Steroidal Anti-Inflammatory Drugs
      • Opioid
      • Anti-Depressants
      • Anti-Seizure
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospitals Pharmacies
      • Retail Pharmacies & Stores
      • Online Pharmacies
    • Market Analysis, Insights and Forecast – By Country
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa

TOC Continued….!!!

Request for Customization:

Have a Look at Related Reports:

Diabetic Retinopathy Treatment Market Size, Share and Global Trend By Diabetic Retinopathy Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy), By Treatment Type (Anti-Vascular Endothelial Growth Factor (VEGF) Drug, Laser Surgery, Vitrectomy, Intraocular Steroid Injection), By End User (Hospitals, Ophthalmic Centres, Ambulatory Surgery Centres, Others) and Geography Forecast till 2026

Diabetes Socks Market Size, Share & Industry Analysis, By Features (Regular Socks, Smart Socks), By Gender (Men,Women, Unisex), By Distribution Channel (Retail Stores, Hospital Pharmacies, E-commerce) and Regional Forecast, 2019-2026

Diabetes Monitoring Devices Market Size, Share and Global Trend by Product (Blood Glucose Meters, Test Strips, Lancets), Distribution Channel (Institutional Sales, Retail Sales) & Geography Forecast till 2026

Diabetes Drugs Market Size, Share and Global Trend By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Geography Forecast till 2026

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/diabetic-neuropathy-market-9858